<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The mechanism involved in the association between <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and <z:mp ids='MP_0005048'>thrombosis</z:mp> or fetal loss remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the biosynthesis of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> and prostacyclin in 31 samples from 25 patients with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and in 32 controls </plain></SENT>
<SENT sid="2" pm="."><plain>The urinary excretion of the major <z:chebi fb="0" ids="26995">thromboxane</z:chebi> metabolite of platelet origin (<z:chebi fb="0" ids="28667">11-dehydrothromboxane B2</z:chebi>) was very significantly increased (P less than .0003) in the patients </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, the urinary metabolite reflecting the vascular production of prostacyclin (2,3-dinor-6-keto-<z:chebi fb="0" ids="28852">prostaglandin F1 alpha</z:chebi>) was much less increased (P less than .02) </plain></SENT>
<SENT sid="4" pm="."><plain>We found no correlation between the levels of anticardiolipin antibodies and the urinary excretion of <z:chebi fb="0" ids="28667">11-dehydro-thromboxane B2</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Six patients with elevated urinary <z:chebi fb="0" ids="28667">11-dehydrothromboxane B2</z:chebi> were treated with low-dose aspirin (20 mg/d during 7 days) </plain></SENT>
<SENT sid="6" pm="."><plain>In these patients, there was a close relationship between the extent of inhibition of the <z:chebi fb="0" ids="26995">thromboxane</z:chebi> urinary metabolite (72%) and serum <z:chebi fb="0" ids="28728">thromboxane B2</z:chebi> (79%) </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, the urinary excretion of 2,3-dinor-6-ketoprostaglandin F1 alpha was nearly unchanged (13% reduction) </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, the F(ab')2 fragments isolated from six patients presenting increased urinary <z:chebi fb="0" ids="28667">11-dehydro-thromboxane B2</z:chebi> enhanced the generation of <z:chebi fb="0" ids="28728">thromboxane B2</z:chebi> (P = .04) and the release of <z:chebi fb="32" ids="36927">14C</z:chebi> <z:chebi fb="19" ids="28790">serotonin</z:chebi> (P = .009) by <z:mpath ids='MPATH_458'>normal</z:mpath> washed platelets, as compared with F(ab')2 from controls </plain></SENT>
<SENT sid="9" pm="."><plain>In summary, our study shows that in patients with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, platelet activation may occur without a compensatory increment in the vascular biosynthesis of prostacyclin </plain></SENT>
<SENT sid="10" pm="."><plain>This observation may be crucial to cause or reflect an increased risk for <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, our results may suggest a rationale for antiplatelet agents for the prophylaxis of <z:mp ids='MP_0005048'>thrombosis</z:mp> in many patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>